Representing uncertainty: The role of cost-effectiveness acceptability curves

Health Economics

Volumn 10, Issue 8, 2001, Pages 779-787

  Fenwick, Elisabeth ^a   Claxton, Karl ^a   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness acceptability curves; Cost effectiveness acceptability frontiers; Decision making; Net benefits; Uncertainty

Indexed keywords

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; MEDICAL DECISION MAKING; METHODOLOGY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HUMANS; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0035669803     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.635     Document Type: Article

References (17)

1. Costs, effects and C/E ratios alongside a clinical trial
2. A Bayesian approach to stochastic cost-effectiveness analysis
3. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
4. Handling uncertainty when performing economic evaluation of healthcare interventions
5. Inference for the C/E acceptability curve and C/E ratio
6. Definition, interpretation and calculation of cost-effectiveness acceptability curves
7. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
8. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41)
9. Improving the efficiency and relevance of health technology assessment: The role of iterative decision analytic modelling
10. Going beyond the single number: Using probabilistic risk assessment to improve risk management
11. The decision rules of cost-effectiveness analysis
12. An economic approach to clinical trial design and research priority setting
13. Net Health Benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
14. Incorporating option values into the economic evaluation of health care technologies
15. The irrelevance of inference: A decision making approach to the stochastic evaluation of health care technologies
16. On the decision rules of cost-effectiveness analysis
17. Low doses versus high doses of angiotensin converting enzyme inhibitor lisinopril in chronic heart failure: A cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival Analysis (ATLAS) study